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Progranulin (PGRN) is a 68.5-kDa glycoprotein containing 7.5 tandem repeats of a 
cysteine-rich motif, and also known as granulin, epithelin precursor, PC cell-derived 
growth factor, proepithelin, and acrogranin. PGRN is involved in multiple physiological 
functions and various disease processes, including autoimmune disorders, tumorigenesis, 
and insulin resistance. In the human brain, heterozygous mutation of the GRN gene is 
one of the major factors causing frontotemporal lobar degeneration (FTLD), which is 
characterized by ubiquitinated cytoplasmic inclusions containing trans-activation 
responsive region DNA binding protein of 43 kDa (TDP-43). Additionally, patients with 
the homozygous mutation present with adult onset neuronal ceroid lipofuscinosis (NCL) 
in humans. PGRN deficiency also increases the risk of developing Alzheimer’s disease 
(AD), and modifies the course of amyotrophic lateral sclerosis (ALS). However, the 
relation between PGRN deficiency and pathogenesis of these neurodegenerative diseases 
was poorly understood. The present study was undertaken to elucidate the possible 
pathophysiological roles of PGRN in protecting the brain from neurodegeneration. 
 
The neurodegenerative diseases as a result of PGRN deficiency are generally 
accompanied by neuroinflammation. Neuroinflammation is characterized by activated 
 
 
 
	 
microglia and astrocytes. Microglia, the resident innate immune cell in the brain, has 
been implicated as an active contributor to neuronal damage in neurodegenerative 
diseases. Interestingly, it has been shown that PGRN levels increase after traumatic brain 
injury (TBI), and activated microglia predominantly express PGRN. Macrophages from 
PGRN-deficient (KO) mice secrete higher levels of proinflammatory cytokines than 
those from wild-type (WT) mice. Furthermore, gliosis in aged mice was facilitated by 
PGRN deficiency. These observations suggest that PGRN is involved in the activation of 
microglia. In Chapter 1, to investigate the role of PGRN in inflammatory responses 
related to activated microglia, mice (8- to 9-week-old) were subjected to experimental 
TBI, which is accompanied by neuroinflammation. PGRN expression was increased in 
association with neuroinflammation after TBI. Further, The study by using 
double-immunostaining showed that PGRN-immunoreactive (IR) cells were mainly 
overlapped with CD68-IR cells, suggesting that the main source of PGRN was 
CD68-positive activated microglia. Next, immunoreactivity and expression of Iba1, 
CD68, and CD11b as markers for activated microglia were compared between WT and 
KO mice. The number of Iba1- and CD11b-IR cells and gene expression of Iba1 and 
CD11b were not significantly different between WT and KO mice, while the number of 
CD68-IR cells and CD68 expression in KO mice were significantly greater than those in 
WT mice. Further, double-immunohistochemical study showed that CD68-positive 
microglia expressed TGFβ1, and TGFβ1 expression and Smad3 phosphorylation in KO 
mice were elevated compared to WT mice. Double-immunostaining between pSmad3 
and GFAP revealed that TGFβ1-Smad3 signal mainly increased in astrocytes. In 
addition, the levels of protein carbonyl groups, which reflect protein oxidation, and 
laminin immunoreactivity, which is associated with angiogenesis, were also significantly 
increased in KO mice compared to WT mice. These results suggest that PGRN is 
produced in CD68-positive microglia after TBI and suppresses excessive inflammatory 
responses related to activated microglia including astrogliosis, oxidative stress, and 
angiogenesis, which are at least partially mediated by TGFβ1.  
 
As mentioned above, it has been demonstrated that patients with the homozygous 
mutation in PGRN gene present with NCL, and there is growing evidence that PGRN is 
related to lysosomal function. CD68 is a member of the lysosome-associated membrane 
protein (Lamp) family that is restrictedly expressed in cells of the monocyte/macrophage 
lineage, and predominately localize to endosomal and lysosomal compartments with a 
modest level of cell surface expression. It has been shown that a profusion of 
CD68-positive microglia appears in the cortex of model mice of mucopolysaccharidosis I 
 
 
 
	 
and IIIB, a type of lysosomal storage disease, and PGRN expression are up-regulated as 
well. The major contributor in the regulation of lysosomal gene expression is 
transcription factor EB (TFEB), and lysosomal gene expressions are up-regulated by 
TFEB translocation from the cytoplasm to the nucleus, and the translocation of TFEB is 
controlled by the mammalian target of rapamycin complex 1 (mTORC1). The 
translocated TFEB binds to the coordinated lysosomal expression and regulation 
(CLEAR) consensus sequence, which leads to an increase in the expression of lysosomal 
genes. Therefore, in Chapter 2, the possible role of PGRN in regulating lysosomes of 
activated microglia in the cerebral cortex after TBI was investigated using 8 to 
10-week-old mice. First, the author found that the mouse Grn gene has two possible 
CLEAR sequences in the promoter region. After TBI, PGRN was colocalized with 
Lamp1, a lysosomal marker, and Lamp1-positive areas in KO mice were significantly 
expanded compared with WT mice. Expression of all the lysosome-related genes 
examined in KO mice was also significantly higher than that in WT mice. The number of 
activated microglia with TFEB localized to the nucleus was also significantly increased 
in KO as compared with WT mice. Since the TFEB translocation is regulated by 
mTORC1 activity in the lysosome, ribosomal S6 kinase 1 (S6K1) phosphorylation that 
reflects mTORC1 activity was compared between WT and KO mice. S6K1 
phosphorylation in KO mice was significantly lower than that in WT mice. In addition, 
the number of nissl-positive living neurons and fluoro-jade B-positive degenerating 
neurons around the injury was significantly decreased and increased, respectively, in KO 
as compared with WT mice. These results suggest that PGRN localized in the lysosome 
is involved in the activation of mTORC1, and its deficiency leads to increased TFEB 
nuclear translocation with a resultant increase in lysosomal biogenesis in activated 
microglia and exacerbated neuronal damage in the cerebral cortex after TBI. 
 
The results of Chapter 1 and 2 suggested that PGRN is involved in regulating 
neuroinflammation by decreasing lysosomal biogenesis. As mentioned above, 
haploinsufficiency of GRN gene in human is one of the major factors causing FTLD, 
which is characterized by ubiquitinated cytoplasmic inclusions containing TDP-43. 
However, the mechanism by which impaired production of PGRN causes the formation 
of TDP-43 inclusions in the cytoplasm remains unclear. In addition, although patients 
with a homozygous GRN mutation present with NCL, characterization of the brain 
pathology regarding NCL in PGRN-deficient mice has yet to be performed. Therefore, in 
Chapter 3, the relationship between lysosomes and disorders resulting from PGRN 
deficiency was investigated using 10- and 90-week-old WT and KO mice. Lysosomal 
 
 
 
	 
biogenesis and gliosis in KO mice were exacerbated with aging as compared with WT 
mice in the ventral posteromedial nucleus/ventral posterolateral nucleus (VPM/VPL), 
where reported NCL model animals show a particular vulnerability early in disease 
progression. The aggregates of p62, which is selectively degraded by 
autophagy-lysosomal system, were observed in neuronal and glial cells in the VPM/VPL 
of aged KO mice. TDP-43 aggregates in the cytoplasm of neurons were also observed in 
the VPM/VPL related to the disrupted autophagy-lysosomal pathway in aged KO mice. 
The NCLs display a relatively uniform phenotype in the central nervous system 
characterized by pronounced gliosis, a dramatic neuronal loss, lipofuscinosis, and 
impaired myelination. Neuronal loss was observed in the VPM/VPL of aged KO mice. 
Additionally, expressions of glial cell-derived cytotoxic factors, i.e., macrophage 
expressed gene 1, cytochrome b-245 light chain, cytochrome b-245 heavy chain, 
complement C4, tumor necrosis factor-α, and lipocalin 2, were increased in aged KO 
mice. Lipofuscinosis in the VPM/VPL and impaired myelination in the cerebral cortex 
were also observed in aged KO mice. These results suggest that PGRN deficiency causes 
exacerbated neuroinflammation including up-regulation of cytotoxic factors, increased 
TDP-43 aggregation in the cytoplasm of neurons and NCL-like pathology with aging, 
and such changes are probably due to lysosomal dysfunction. 
 
The present study suggested that PGRN is involved in modulating lysosomal 
function in activated microglia, and its deficiency causes exacerbated 
neuroinflammation, increased lysosomal biogenesis, gliosis and neuronal loss associated 
with lysosomal dysfunction after TBI as well as aging. Additionally, aged PGRN 
deficient mice accumulated TDP-43 aggreagates in the cytoplasm of neurons and 
exhibited NCL-like pathology, and thus could be useful experimental models for both 
FTLD and NCL caused by PGRN deficiency in humans. Previous studies have shown 
that PGRN plays an essential role in the pathoetiology of neurodegenerative diseases 
such as FTLD, NCL, AD, and ALS. It has been also shown that impaired lysosomal 
functions are involved in the pathogenesis of these neurodegenerative diseases. Taken 
together, lysosomal dysfunction might be a common process in the pathogenic 
mechanisms of such neurodegenerative diseases resulting from PGRN deficiency. 
Further studies on the detailed mechanisms by which PGRN regulates lysosomal 
function may contribute a great deal to develop therapeutic methods for 
neurodegenerative diseases related to lysosomal dysfunction. 
